C. difficile-associated diarrhea (Infants, Children, and Adolescents): PO 40 mg/kg/DAY divided TID or QID for 7 to 10 days. Max 2000 mg/DAY.For severe or recurrent infection (Oral, rectal enema): 40 mg/kg/DAY divided QID for ≥10 days; Max dose 2000 mg/day; if complete ileus, rectal enema dosage form may be preferable. Note that therapeutic interchange for adults suggests dosing of 125 mg PO QID.
There are no dosage adjustments provided in the manufacturer's labeling; however, dosage adjustment unlikely due to low systemic absorption.
There are no dosage adjustments provided in manufacturer's labeling; however, dosage adjustment unlikely due to low systemic absorption.
Only indication is in the therapy of C. difficile infection, particularly recurrent or severe disease
Possibility of accumulation in severe renal dysfunction; consider checking a vancomycin level in dialysis patients
Avoid concurrent administration of oral vancomycin and bile acid sequestrants (may dimish therapeutic effect of vancomycin).
No oral absorption.
May increase vancomycin resistant enterococci colonization in the gut
Cost listed above reflects oral liquid. Capsules are almost 10X more costly
Antimicrobial class: glycopeptide
Average serum half life: serum half life not available due to low systemic absorption
Route of Elimination: Primarily feces as limited absorption
